Delving into the Latest Updates on Troxerutin with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Hydroxyethyrutin, Iroxerutin, RUTIN/RUTINUM

+ [43]

Target-

Action-

Mechanism-

Therapeutic Areas

Cardiovascular Diseases

Active Indication

Cardiovascular Diseases

Inactive Indication-

Originator Organization

Shaanxi Dunsi Pharmaceutical Co Ltd

Active Organization

Shaanxi Dunsi Pharmaceutical Co Ltd

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date

China (01 Jan 1982),

Cardiovascular Diseases

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC33H42O19

InChIKeyIYVFNTXFRYQLRP-VVSTWUKXSA-N

CAS Registry7085-55-4

The goal of this clinical trial is to learn if troxerutin works to prevent thrombotic events in mild or severe COVID-19 patients. It will also learn about the safety of troxerutin. The main questions it aims to answer are:
* Does troxerutin lower the number of thrombotic events in participants?
* What medical problems do participants have when taking troxerutin? Researchers will compare troxerutin to a placebo (a look-alike substance that contains no drug) to see if troxerutin works to prevent thrombotic events in COVID-19 patients.
Participants will:
* Take troxerutin or a placebo every day for 7 days.
* Visit the clinic at the first, fourth, seventh and 28th days after enrollment for checkups and tests
* Keep a diary of their symptoms and the number of times of thrombotic events, bleeding events and type II HIT-related thrombocytopenia

Start Date15 Dec 2023

Sponsor / Collaborator

University of Westlake

NCT05113420

/ Unknown statusNot ApplicableIIT

The Efficacy and Safety of Different Phlebotonic Drugs in Children With Venous Malformations: a Prospective Cohort Study

The aim of this study is to evaluate the efficacy and safety of different phlebotonic drugs in children and to assess patient satisfaction after treatment.

Start Date17 Sep 2019

Sponsor / Collaborator-

100 Clinical Results associated with Troxerutin

Login to view more data

100 Translational Medicine associated with Troxerutin

Login to view more data

100 Patents (Medical) associated with Troxerutin

Login to view more data

743

Literatures (Medical) associated with Troxerutin

01 Jul 2025·Journal of Inorganic Biochemistry

Structural related oxidovanadium(IV)-flavonoid complexes. Influence on their anticancer effects

Article

Author: Huamaní, Ángel L ; Williams, Patricia A M ; Naso, Luciana G ; López Tevez, Libertad L ; Ferrer, Evelina G ; Gonzalez, Pablo J ; Martínez Medina, Juan J ; Restrepo, Andrés G ; Velásquez Bravo, Alexandra

Flavonoids, known for their antioxidant properties in plants, can also act as pro-oxidants in cancer cells, an effect that intensifies when coordinated with metal cations. Among them, oxidovanadium(IV) (VO) complexes with flavonoids have shown promising anticancer potential, following a clear relationship of the ligand structure with the activity. Quercetin and troxerutin share a common core structure; however, in troxerutin, four of the five hydroxyl (-OH) groups of quercetin are blocked, which may influence its metal coordination properties. In this study, we synthesized and fully characterized the VOtroxerutin complex using FTIR, EPR, UV-Vis, and reflectance spectroscopies, along with elemental, thermal, and conductivity analyses. Additionally, we prepared the reported VOquercetin complex, which shares the same coordination sphere as VOtroxerutin, to explore a relationship between the structure of the complexes and their activities. Their anticancer potential was tested through in vitro cytotoxicity assays against the A549 human lung cancer cells and HaCaT normal human keratinocytes. Both complexes exhibited anticancer activities (viability inhibition at 100 μM: 32.1 %, VOtroxerutin; 39.5 %,VOquercetin) and selectivity, highlighting their therapeutic potential. Notably, their pro-oxidant effects were activated upon incubation with cancer cells, leading to oxidative stress-induced cytotoxicity and mitochondrial membrane disruption. Further comparisons with the VOrutin complex provided additional insights into the correlation between anticancer activity and the coordination environment of the VOFlavonoid complexes. Additionally, we evaluated the safety profile of VOtroxerutin, finding no acute toxicity or mutagenic effects, supporting its potential as a targeted anticancer therapy with normal cells viability inhibition only at 100 μM (10 %).

01 Mar 2025·International Immunopharmacology

Neuromodulatory effect of troxerutin against doxorubicin and cyclophosphamide-induced cognitive impairment in rats: Potential crosstalk between gut–brain and NLRP3 inflammasome axes

Article

Author: Gamal, Nada K ; George, Mina Y ; Ayoub, Iriny M ; El-Naga, Reem N

"Chemobrain" refers to the cognitive impairment induced by chemotherapy. The doxorubicin and cyclophosphamide cocktail has been used for various cancers, especially breast cancer. However, both have been linked to chemobrain as well as gastrointestinal toxicity. Despite being distinct organs, the gut and the brain have a bidirectional connection between them known as the gut-brain axis. This research aimed to study the neuroprotective effect of troxerutin, a rutin derivative, in chemobrain induced by doxorubicin and cyclophosphamide via a potential impact on the gut-inflammasome-brain axis. Troxerutin was administered at 75, 150, and 300 mg/kg doses. Furthermore, behavioral, histological, and acetylcholinesterase assessments were performed. Accordingly, the highest dose of troxerutin was selected to investigate the potential underlying mechanisms. Troxerutin treatment reversed the chemotherapy-fecal metabolite alterations. Additionally, troxerutin demonstrated positive effects against deterioration of intestinal integrity, permeability, and microbial endotoxins translocation, as evidenced by its effect on tight junction proteins; ZO-1, and claudin-1 expression, and lipopolysaccharide serum levels. Consequently, troxerutin hindered lipopolysaccharide-induced oxidative damage, systemic inflammation, and neuroinflammation. Moreover, troxerutin demonstrated antioxidant effects via its impact on lipid peroxidation, catalase levels, and the Nrf2/HO-1 pathway. Furthermore, chemotherapy-induced inflammation was opposed by troxerutin via downregulation of NLRP3, caspase-1, and the downstream cytokines; IL-18 and IL-1β. Importantly, troxerutin did not abrogate the anticancer activity of doxorubicin and cyclophosphamide in human MCF7 cells. Collectively, our study suggested the potentiality of troxerutin as a therapeutic choice against chemobrain by inhibiting the gut-inflammasome-brain axis and hindering acetylcholinesterase, oxidative stress, and neuroinflammation.

01 Jan 2025·Food Chemistry

Integrating mineral elements and metabolite features to distinguish Lotus seeds from different geographic origins

Article

Author: Luo, Liping ; Liu, Tao ; Li, Zhuozhen ; Yu, Wenjie ; Su, Haoran

The characteristics of lotus seeds (LS) are influenced by variety and environment. However, it remains unknown the difference of metabolites and elements of LS from different origins. In this study, an accurate quantification method (97-107 %) for 20 mineral elements in LS was developed, and a metabolomic method was established to identify a total of 323 metabolites in LS. Mineral composition analysis revealed significant variations in the mineral element contents among LS samples from seven geographical regions. LS were rich in potassium (14,710 mg/kg), manganese (67.19 mg/kg), with a low level of sodium (210 mg/kg). A total of 10 mineral elements and 117 metabolites (p < 0.05 and VIP > 1) were identified as the potential geographical markers of LS by integration analysis. The linear discriminant analysis model showed high prediction accuracy. This study provides strong experimental evidence to maintain the authenticity and quality of LS in the food industry.

100 Deals associated with Troxerutin

Login to view more data